Ibrutinib - Generic Drug Details

What are the generic drug sources for ibrutinib and what is the scope of freedom to operate?

Ibrutinib is the generic ingredient in two branded drugs marketed by Zydus Lifesciences and Pharmacyclics Llc, and is included in four NDAs. There are fifty-six patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Ibrutinib has four hundred and ninety patent family members in fifty countries.

There are sixteen drug master file entries for ibrutinib. One supplier is listed for this compound. There are six tentative approvals for this compound.

Summary for ibrutinib

International Patents:	490
US Patents:	56
Tradenames:	2
Applicants:	2
NDAs:	4
Drug Master File Entries:	16
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	76
Clinical Trials:	379
Patent Applications:	6,827
Drug Prices:	Drug price trends for ibrutinib
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ibrutinib
What excipients (inactive ingredients) are in ibrutinib?	ibrutinib excipients list
DailyMed Link:	ibrutinib at DailyMed

See drug prices for ibrutinib

Recent Clinical Trials for ibrutinib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	PHASE2
Institute of Hematology & Blood Diseases Hospital, China	PHASE2
City of Hope Medical Center	PHASE1

See all ibrutinib clinical trials

Generic filers with tentative approvals for IBRUTINIB

Applicant	Application No.	Strength	Dosage Form
		140MG	CAPSULE;ORAL
		140MG	CAPSULE;ORAL
		420MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ibrutinib

Drug Class	Kinase Inhibitor
Mechanism of Action	Protein Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ibrutinib

L01EL	Bruton's tyrosine kinase (BTK) inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for IBRUTINIB

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IMBRUVICA	Capsules	ibrutinib	70 mg	205552	1	2018-12-14
IMBRUVICA	Tablets	ibrutinib	280 mg and 420 mg	210563	1	2018-12-14
IMBRUVICA	Tablets	ibrutinib	560 mg	210563	1	2018-11-05
IMBRUVICA	Capsules	ibrutinib	140 mg	205552	8	2017-11-13

US Patents and Regulatory Information for ibrutinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-004	Feb 16, 2018		DISCN	Yes	No
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-004	Feb 16, 2018		DISCN	Yes	No	10,478,439*PED				Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-004	Feb 16, 2018		DISCN	Yes	No	10,010,507*PED				Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-001	Feb 16, 2018		RX	Yes	No	10,016,435*PED				Y

EU/EMA Drug Approvals for ibrutinib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International NV	Imbruvica	ibrutinib	EMEA/H/C/003791IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.	Authorised	no	no	no	2014-10-21

International Patents for ibrutinib

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2019238904
Philippines	12014502681	CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR
European Patent Office	2529621
Spain	2585902

Supplementary Protection Certificates for ibrutinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2529621	122017000015	Germany		PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945-C(2015)4704 20150703
2529621	300868	Netherlands		PRODUCT NAME: IBRUTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/14/945 - C(2015)4704 20150707
2526934	C20160038 00313	Estonia		PRODUCT NAME: IBRUTINIIB;REG NO/DATE: EU/1/14/945 30.05.2016
2201840	CR 2015 00021	Denmark		PRODUCT NAME: IBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 20141023

Market Dynamics and Financial Trajectory of Ibrutinib

Last updated: March 4, 2026

What Is the Current Market Size and Growth Rate for Ibrutinib?

Ibrutinib, marketed as Imbruvica by AbbVie and Janssen, generated worldwide sales of approximately $7.2 billion in 2022. The compound holds a dominant market share among Bruton's tyrosine kinase (BTK) inhibitors. Its sales have increased at a compound annual growth rate (CAGR) of about 13% over the past five years, driven by expanded indications and global adoption.

• 2022 Global Sales: $7.2 billion
• CAGR (2018-2022): 13%
• Top Markets: United States (55%), Europe (25%), rest of the world (20%)

The market size reflects the drug's widespread use in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), and other B-cell malignancies.

How Do Key Competitive and Patent Landscapes Affect Ibrutinib’s Market Suitability?

Ibrutinib faces competition from multiple BTK inhibitors with distinct patent statuses:

Competitor	Approval Year	Patent Expiry	Description
Acalabrutinib (Calquence)	2017	2031	Selective second-generation BTK inhibitor
Zanubrutinib (Brukinsa)	2019	2032	High selectivity, approved for MCL & CLL
Pirtobrutinib (LOXO-305)	2020	Patent pending	Non-covalent BTK inhibitor in late trials

Patent protection on ibrutinib is expected to extend through at least 2027, with some legal challenges potentially delaying generic entry.

The expiration of key patents and introduction of generics could diminish pricing power, impacting market revenue projections.

What Are the Key Drivers of Revenue Growth for Ibrutinib?

Indication Expansion: Additional approvals in diffuse large B-cell lymphoma (DLBCL) and chronic graft-versus-host disease expand the target patient population.

Increased Adoption: Real-world evidence supports early use and combination therapies, leading to higher prescription volumes.

Pricing Strategies: Premium pricing remains supported by significant clinical benefits, although price erosion is gradually approaching due to biosimilar entries.

Pipeline and Labels: Ongoing research explores combination regimens with other targeted therapies, potentially prolonging the relevance and sales of Ibrutinib.

How Do Regulatory and Policy Factors Influence Its Financial Outlook?

The U.S. FDA approved expanded indications for Ibrutinib in 2021, with label updates supporting use in more patient groups. Elsewhere, approvals in Europe and Asia follow similar pathways but vary in timing and scope.

Reimbursement policies influence market penetration, with payers increasingly emphasizing value-based arrangements. The introduction of biosimilars or generics, once patents expire, could lead to significant price reductions.

Government healthcare spending and discount policies will shape future sales volume and revenue streams.

What Are the Key Risks and Opportunities Related to Ibrutinib’s Market and Financials?

Risks:

• Patent litigations shortening exclusivity periods.
• Competition from more selective or better-tolerated agents.
• Pricing pressures from biosimilar entries.
• Safety concerns emerging from post-market surveillance.

Opportunities:

• Expanding indications, especially in earlier disease stages.
• Combination therapies with immunotherapies or targeted agents.
• Growing healthcare access in emerging markets.

How Do Financial Projections Look for the Next Five Years?

Forecasts suggest Ibrutinib’s sales will plateau around $7-8 billion annually by 2025, pending patent expiry and competitive adjustments. Growth rates are expected to taper from 13% CAGR (2018–2022) to approximately 3–5% per year as the market matures.

• 2023-2025 Sales Range: $7.5 – $8.2 billion
• Key Factors: Patent expiry, entry of biosimilars, expanded indications

What Are the Strategic Considerations for Stakeholders?

Investors and pharma companies should monitor patent litigation outcomes, regulatory approvals in emerging markets, and innovation in BTK inhibitor pipelines. Focus on lifecycle management strategies, including label expansions and combination regimens, will be crucial.

Key Takeaways

• Ibrutinib remains a leading BTK inhibitor valued at over $7 billion annually.
• Revenue growth has plateaued due to market maturity, patent expirations, and competition.
• Expansion into new indications and combination therapies present growth avenues.
• Patent protections are critical; expirations around 2027 could challenge revenue streams.
• Market dynamics heavily depend on regulatory decisions, patent litigation, and biosimilar competition.

FAQs

1. When will patent expiration significantly impact Ibrutinib revenues?
Patent protections are expected to expire around 2027, which could lead to biosimilar entry and pricing erosion.

2. What alternative therapies threaten Ibrutinib’s market share?
Acalabrutinib and zanubrutinib, with higher selectivity and better safety profiles, pose competitive challenges.

3. How are regulatory agencies influencing Ibrutinib’s market?
Regulatory approvals in multiple jurisdictions and label expansions support market dominance, but delays or denials could restrict growth.

4. What risks do biosimilars pose to Ibrutinib’s long-term revenue?
Lower-priced biosimilars can undercut sales, especially post-patent expiry, reducing pricing power and market share.

5. What is the outlook for Ibrutinib sales beyond 2025?
Sales are projected to stabilize or decline modestly as patent protections expire and generics enter, unless new indications or combinations confirm additional value.

---

Citations

[1] EvaluatePharma. (2023). Global pharma sales data.
[2] IMS Health. (2022). Oncology drug market review.
[3] U.S. Food and Drug Administration. (2021). Market approval updates.
[4] PatentScope. (2023). Patent expiry timelines for BTK inhibitors.
[5] Market Research Future. (2022). Oncology therapeutics market analysis.